New Studies Emphasise Safety And Efficacy Of PREVICOX

Two recent publications continue to demonstrate the efficacy and safety profile of Merial’s canine NSAID PREVICOX®. Launched in 2005, PREVICOX®, the first canine coxib NSAID to be introduced to the UK, is supported by five years clinical experience in veterinary practice, in addition to many published studies. In their study, Lecoindre and Pepin? evaluated the beneficial effects of once daily administration of 5mg/kg PREVICOX to dogs suffering from osteoarthritis (OA) for 90 days. Response to treatment was excellent, with significant improvements observed in lameness scores, pain on manipulation of the affected joint and range of motion. Of particular note was the fact that the degree of improvement increased with duration of treatment, clearly demonstrating the benefits of longer term treatment. These results support the findings of a recent review of the safety and efficacy of long-term NSAID use in dogs with OA?. The product’s safety profile was also evaluated by means of biochemistry and haematology assessments. In addition, regular gastroscopic examinations were used to directly visualise the effect of treatment on the gastric mucosa. These safety assessments demonstrated that PREVICOX® therapy was well tolerated, with no significant treatment related changes seen on biochemistry or gastroscopy, despite the fact that this was a geriatric population which included a number of dogs with a prior history of gastrointestinal tract disease. The findings from a different study by Joubert?, published in the South African Veterinary Journal, provide further confirmation of the beneficial effects of 90 days PREVICOX® treatment in a geriatric population of dogs. Commenting on the results of the two studies, Kevin Whelan, Merial’s Veterinary Technical Manager said, “The outcome from these studies provide further evidence for the benefits of long term use of PREVICOX® in dogs suffering from osteoarthritis. There is relatively little published information available on the use of NSAIDs in older dogs, and these results confirm that PREVICOX® is well tolerated in this group of patients.” For further information about PREVICOX®, and to find out how Merial can help your practice to ensure that more dogs with OA benefit from treatment, please contact your local Territory Manager or call 0870 6000 123.

More from

• West Midlands communications agency celebrates quartet of award nominations for work in veterinary sector
• IVC Evidensia assembles expert team to run new £10m referral hospital
• Home delivery service can increase pet health plan sign-ups by 25%
• Research reveals vital clues to help fight anthelmintic resistance
• Lifetime Achievement Award recognises Harrogate vet’s dedication to improving the health and welfare of rabbits